Poul Mojdeh 4

What Happened

• Poul Mojdeh, President & CEO and a director of Integra Lifesciences (IART), was granted 343,393 restricted stock units (reported as an acquisition at $0) on March 11, 2026. The Form 4 records the award as a derivative grant (code A) rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-03-11; Form 4 filed: 2026-03-12 (appears timely).
• Grant size: 343,393 RSUs reported at $0.00 (RSUs are a non‑cash award; the filing shows no purchase price).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting/other terms (from filing footnote): RSUs vest in three equal annual installments on the first, second and third anniversaries of the 3/11/2026 grant. Delivery is treated as deferred compensation — shares will be delivered within 30 days after the first business day following the six‑month period after the insider’s separation of service. Accelerated vesting applies upon death, disability, or a qualifying termination within 24 months after a change in control.

Context

• RSUs are a common form of executive compensation; the Form 4 shows acquisition at $0 because these are a grant, not a market purchase. The economic value equals the company’s share price times 343,393 on the grant/vesting dates (that market value is not listed in this filing).
• This transaction is an award (not a sale), so it does not by itself signal buying or selling intent by the insider; it reflects compensation and long‑term retention terms set by the company.